# AVANT

April 12, 2023

# Condensed Interim Consolidated Financial Statements

(Unaudited - Expressed in Canadian dollars)

Three Months Ending February 28, 2023

# **TABLE OF CONTENTS**

Condensed Interim Consolidated Statements of Financial Position	3
Condensed Interim Consolidated Statements of Comprehensive (Loss) Income	4
Condensed Interim Consolidated Statements of Changes in Equity	5
Condensed Interim Consolidated Statements of Cash Flows	6
Notes to the Condensed Interim Consolidated Financial Statements	7-24

# **Condensed Interim Consolidated Statements of Financial Position**

As at February 28, 2023 and November 30, 2022

(Unaudited, Expressed in Thousands of Canadian Dollars Except Share Amounts)

	Note	Febi	ruary 28, 2023	November 30, 2022	
Assets			-		
Current assets					
Cash and cash equivalents		\$	2,588	\$	6,764
Accounts receivable	4		6,996		4,409
Prepaid expenses	5		2,043		1,691
Biological assets	6		4,193		4,146
Inventory	7		13,195		10,461
Marketable Securities			19		16
			29,034		27,487
Property, plant and equipment	9,11		40,160		28,651
Goodwill	8,11		6,024		6,024
Intangible assets	8,11		3,404		3,869
Investment in joint venture	10		· -		1,000
Total assets		\$	78,622	\$	67,031
Liabilities					
Current liabilities					
Accounts payable and accrued liabilities	18	\$	4,543	\$	2,683
Lease liabilities	13		717		611
Convertible debenture - current	12,14		6,334		<u>-</u>
			11,594		3,294
Amount due to non-controlling interests	11		1,005		11,989
Lease liabilities	13		5,598		2,400
Convertible debenture – non-current	12,14		2,646		-
Deferred tax liability			1,105		1,105
Total liabilities			21,948		18,788
Shareholders' equity					
Share capital	15		100,395		94,542
Contributed surplus	15		9,319		8,666
Accumulated deficit			(58,310)		(59,289)
Equity attributable to equity holders of the parent			51,404		43,919
Non-controlling interests	12		5,270		4,324
Total shareholders' equity			56,674		48,243
Total liabilities and shareholders' equity		\$	78,622	\$	67,031

Nature and continuance of operations (Note 1) Commitments and contingencies (Note 21) Subsequent events (Note 22)

Approved on behalf of the Board on April 12, 2023:

/s/ Duane Lo, Director

/s/ Derek Sanders, Director

# **Condensed Interim Consolidated Statements of Comprehensive Income (Loss)**

For the three-month periods ended February 28, 2023 and February 28, 2022

(Unaudited, Expressed in Thousands of Canadian Dollars Except Share Amounts)

	Note	Feb	ruary 28, 2023		February 28, 2022
Revenue		\$	7,874	\$	4,614
Excise taxes		Ψ	(845)	Ψ	(417)
Net revenue	17		7,029		4,197
Cost of sales	.,		(4,104)		(3,243)
Gross margin before fair value changes			2,925		954
Unrealized gain on changes in fair value of biological assets			3,379		822
Change in fair value of biological assets realized through inventory sold			(3,313)		(1,081)
Gross margin			2,991		695
Operating expenses					
Administration and general			415		69
Business fees and licenses			274		219
Consulting fees			132		136
Depreciation and amortization	8,9		532		420
Marketing and advertising			65		120
Professional fees			500		222
Salaries and wages			731		500
Share based payments	16		321		22
Travel			47		38
			3,017		1,746
Net loss from operations			(26)		(1,051)
Other income (expense)			_		<u>-</u> \
Gain (loss) on marketable securities			3		(117)
Financing costs			(12)		(12)
Equity income on investment in associate	10		-		581
Gain on legal settlement			-		104
Other income			27		
Net loss and comprehensive loss		\$	(8)	\$	(495)
Attributable to:					
Equity holders of the parent			124		(495)
Non-controlling interests	12		(132)		-
Loss per common share					
Basic and fully diluted		\$	(0.00)	\$	(0.00)
Weighted average shares outstanding					
Basic and fully diluted			216,028,724		200,502,997

# **Condensed Interim Consolidated Statements of Changes in Equity**

For the three-month periods ended February 28, 2023 and February 28, 2022

(Unaudited, Expressed in Thousands of Canadian Dollars Except Share Amounts)

Attributable to equity holders of the Company											
	Shares (000's)		Share capital	Со	ntributed Surplus		Deficit	Equ	uity – NCI		Total
Balance at November 30, 2022	206,094,740	\$	94,542	\$	8,666	\$	(59,289)	\$	4,324	\$	48,243
Net income (loss) for the period	-		· -		-		124		(132)		(8)
Share units released	902,665		279		(355)				, ,		(76)
Shares issued for services	931,406		188		(24)		_		-		164
3PL NCI purchase	22,249,734		3,906		856		1,000		(4,252)		1,510
3PL NCI purchase transaction	, ,		,				•		( , ,		,
costs	-		-		-		(145)		-		(145)
Flowr Okanagan acquisition	7,402,186		1,480		-		-		5,330		6,810
Share-based compensation	-		-		176		-		-		176
Balance at February 28, 2023	237,580,731	\$	100,395	\$	9,319	\$	(58,310)	\$	5,270	\$	56,674
Balance at November 30, 2021	199,591,886	\$	92,744	\$	6,877	\$	(51,747)	\$	(51,747)	\$	47,874
Net loss for the period	-		· -		· -		(495)		(495)		(495)
Shares issued for contingent							,		,		,
consideration for acquisitions	1,000,000		280		(280)		-		-		-
Share-based compensation	-		-		22		-		-		22
Balance at February 28, 2022	200,591,886	\$	93,024	\$	6,619	\$	(52,242)	\$	(52,242)	\$	47,401

# **Condensed Interim Consolidated Statements of Cash Flows**

For the three-month periods ended February 28, 2023 and February 28, 2022

(Unaudited, Expressed in Thousands of Canadian Dollars Except Share Amounts)

		ary 28, 2023	February 28, 2022		
Cash flows from operating activities					
Net loss	\$	(8)	\$	(495)	
Items not affecting cash:					
Depreciation and amortization		1,451		745	
Equity (income) loss on investment in associate		-		(581)	
Financing costs		89		12	
Share-based payments		321		22	
Unrealized gain on changes in fair value of biological assets		(3,379)		(822)	
Change in fair value of biological assets realized through inventory sold		3,313		1,081	
Other income		(27)		-	
(Gain) Loss on marketable securities		(3)		117	
		1,757		79	
Change in non-cash operating working capital:					
Accounts receivable		(1,364)		(1,704)	
Prepaid expenses		505		(18)	
Biological assets		297		(319)	
Inventory		(1,903)		(168)	
Accounts payable and accrued liabilities		1,070		143	
Net cash flows used in operating activities		362		(1,987)	
Cash flows from investing activities					
Investments in associates		-		(413)	
Acquisition of Flowr Okanagan		(1,650)			
Purchase of property and equipment		(923)		(167)	
		(2,573)		(580)	
Cash flows from financing activities					
Lease liability payments		(244)		(95)	
Purchase of non controlling interests		(1,500)		-	
Transaction costs for purchase of non controlling interests		(145)		-	
Share units released		(76)		-	
		(1,965)		(95)	
Decrease in cash and cash equivalents	<u> </u>	(4,176)	<del></del>	(2,662)	
Cash and cash equivalents – beginning of period		6,764		14,313	
Cash and cash equivalents – end of period	\$	2,588	\$	11,651	

#### Notes to the Condensed Interim Consolidated Financial Statements

For the three-month periods ended February 28, 2023 and February 28, 2022

(Unaudited, Expressed in Thousands of Canadian Dollars Except Share Amounts)

# 1 Nature and continuance of operations

Avant Brands Inc. (formerly GTEC Holdings Ltd.) (the "Company") was originally incorporated as a capital pool company under the Canada Business Corporations Act. On July 28, 2017, the Company was continued under the Business Corporations Act (British Columbia). On June 12, 2018, the Company completed its Qualifying Transaction (as defined under the policies of the TSX Venture Exchange), pursuant to a business combination (the "Business Combination") with GreenTec Holdings Ltd. and 1155425 BC Ltd. Following the completion of the Business Combination, the Company changed its name from Black Birch Capital Acquisition III Corp. to GTEC Holdings Ltd.

The Company's Principal business activity is pursuing opportunities in the cannabis industry. The Company is a publicly traded company listed on the Toronto Stock Exchange ("TSX") under the symbol "AVNT" and trades on the OTCQX Best Markets (OTCQX: AVTBF) and Frankfurt Stock Exchange (FRA: 1BU0). The Company's head office is located at Suite 335 – 1632 Dickson Avenue, Kelowna, British Columbia, V1Y 7T2.

These condensed interim consolidated financial statements have been prepared on the basis of accounting principles applicable to a going concern which assumes that the Company will be able to continue for the foreseeable future and will be able to realize its assets and discharge its liabilities in the normal course of business.

The Company has incurred losses since its inception and has an accumulated deficit of \$58,310 as at February 28, 2023, that has been funded primarily by issuance of equity, convertible debentures and advances from related parties. There is a material uncertainty related to these conditions that casts significant doubt about the Company's ability to continue as a going concern and therefore it may be unable to realize its assets and discharge its liabilities in the normal course of business. The Company's ability to continue as a going concern depends upon its ability to generate profitable operations or raise adequate financing in the future.

# 2 Basis of presentation

## Statement of compliance and basis of measurement

The Company's condensed interim consolidated financial statements have been prepared in accordance with IAS 34, *Interim Financial Reporting*. These condensed interim consolidated financial statements do not include all notes of the type normally included within the annual financial report and should be read in conjunction with the audited annual financial statements of the Company as at and for the year ended November 30, 2022, which have been prepared in accordance with International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board (the "IASB") and Interpretations of the IFRS Interpretations Committee.

These condensed interim consolidated financial statements of the Company were approved and authorized for issue by the Board of Directors of the Company on April 12, 2023.

#### **Basis of consolidation**

These consolidated financial statements include the accounts of the Company and the following Canadian subsidiaries:

Subsidiaries	Geographical Region	Ownership percentage
Avant Craft Cannabis Inc. ("ACC")	Edmonton, Alberta	100%
GreenTec Bio-Pharmaceuticals Inc. ("GBP")	Kelowna, British Columbia	100%
GreenTec Holdings Ltd. ("GreenTec")	Kelowna, British Columbia	100%
GreenTec Retail Ventures Inc.	Kelowna, British Columbia	100%
Grey Bruce Farms Incorporated ("Grey Bruce")	Tiverton, Ontario	100%
Spectre Labs Inc.	Kelowna, British Columbia	100%
Tumbleweed Farms Corp. ("Tumbleweed")	Chase, British Columbia	100%
1203648 B.C. Ltd.	Kelowna, British Columbia	100%
3PL Ventures Inc. ("3PL")	Vernon, British Columbia	100%
Avant K1 Brands Inc. ("Avant K1")	Kelowna, British Columbia	50%
The Flowr Group (Okanagan) Inc. ("Flowr Okanagan")	Kelowna, British Columbia	50%

#### Notes to the Condensed Interim Consolidated Financial Statements

For the three-month periods ended February 28, 2023 and February 28, 2022

(Unaudited, Expressed in Thousands of Canadian Dollars Except Share Amounts)

Subsidiaries are entities that the Company controls. Control is defined as the exposure, or rights, to variable returns from involvement with an investee and the ability to affect those returns through power over the investee. Power over an investee exists when the Company has existing rights and the ability to direct the activities that significantly affect the investee's returns. This control is generally evidenced through owning more than 50% of the voting rights or currently exercisable potential voting rights of a company's share capital. All inter-company balances and transactions, including unrealized profits and losses arising from intra-group transactions, have been eliminated upon consolidation.

#### **Significant Accounting Policies**

These unaudited condensed interim consolidated financial statements reflect the accounting policies and disclosures described to the Company's audited consolidated financial statements for the year ended November 30, 2022 with the exception of any new policies set out below and accordingly, should be read in conjunction with those audited consolidated financial statements and the notes thereto.

#### Convertible debentures

Please refer to Note 14 for the convertible debentures account policy disclosure.

#### **Financial instruments**

On initial recognition, a financial asset is classified as measured at: amortized cost; fair value through other comprehensive income ("FVOCI") - debt investment; FVOCI - equity investment; or FVTPL. Financial assets are not reclassified subsequent to their initial recognition unless the Company changes its business model for managing financial assets in which case all affected financial assets are reclassified on the first day of the first reporting period following the change in the business model. Financial assets at FVTPL: These assets are subsequently measured at fair value. Net gains and losses, including any interest or dividend income, are recognized in the statement of comprehensive loss. Financial assets at amortized cost: These assets are subsequently measured at amortized cost using the effective interest method. The amortized cost is reduced by impairment losses. Interest income, foreign exchange gains and losses and impairment are recognized in the statement of loss and comprehensive loss. Any gain or loss on derecognition is recognized in the statement of comprehensive loss. Debt investments at FVOCI: These assets are subsequently measured at fair value. Interest income calculated using the effective interest method, foreign exchange gains and losses and impairment are recognized in the statement of loss and comprehensive loss. Other net gains and losses are recognized in OCI. On derecognition, gains and losses accumulated in OCI are reclassified to the statement of comprehensive loss. Equity investments at FVOCI: These assets are subsequently measured at fair value. Dividends are recognized as income in the statement of loss and comprehensive loss unless the dividend clearly represents a recovery of part of the cost of the investment. Other net gains and losses are recognized in OCI and are never reclassified to the statement of comprehensive loss.

#### **Financial liabilities**

Financial liabilities are classified as measured at amortized cost or FVTPL. A financial liability is classified as FVTPL if it is classified as held-for-trading, it is a derivative or it is designated as such on initial recognition. Financial liabilities at FVTPL are measured at fair value and net gains and losses, including any interest expense, are recognized in the statement of loss and comprehensive loss. Other financial liabilities are subsequently measured at amortized cost using the effective interest method. Interest expense and foreign exchange gains and losses are recognized in the statement of loss and comprehensive loss. Any gain or loss on derecognition is also recognized in the statement of comprehensive loss.

# 3 Adoption of new accounting pronouncements

- a) New IFRS Standards in issue but not yet effective:
- (i) Amendments to IAS 37: Onerous Contracts and the Cost of Fulfilling a Contract

The amendment specifies that 'cost of fulfilling' a contract comprises the 'costs that relate directly to the contract'. Costs that relate directly to a contract can either be incremental costs of fulfilling that contract or an allocation of other costs that relate directly to fulfilling contracts. The amendment is effective for annual periods beginning on or after January 1, 2023 with early application permitted. The Company is currently evaluating the potential impact of these amendments on the Company's consolidated financial statements.

#### Notes to the Condensed Interim Consolidated Financial Statements

For the three-month periods ended February 28, 2023 and February 28, 2022

(Unaudited, Expressed in Thousands of Canadian Dollars Except Share Amounts)

#### (ii) Amendments to IAS 1: Classification of Liabilities as Current or Non-current

The amendment clarifies the requirements relating to determining if a liability should be presented as current or non-current in the statement of financial position. Under the new requirement, the assessment of whether a liability is presented as current or non-current is based on the contractual arrangements in place as at the reporting date and does not impact the amount or timing of recognition. The amendment applies retrospectively for annual reporting periods beginning on or after January 1, 2023. The Company is currently evaluating the potential impact of these amendments on the Company's consolidated financial statements.

#### (iii) Amendments to IAS 12: Deferred Tax related to Assets and Liabilities arising from a Single Transaction

The amendment narrowed the scope of certain recognition exemptions so that it no longer applies to transactions that, on initial recognition, give rise to equal taxable and deductible temporary differences. An entity applies the amendments to transactions that occur on or after the beginning of the earliest comparative period presented. It also, at the beginning of the earliest comparative period presented, recognizes deferred tax for all temporary differences related to leases and decommissioning obligations and recognizes the cumulative effect of initially applying the amendments as an adjustment to the opening balance of retained earnings (or other component of equity, as appropriate) at that date. The amendment is effective for annual periods beginning on or after January 1, 2023 with early application permitted. The Company is currently evaluating the potential impact of these amendments on the Company's consolidated financial statements.

#### (iv) Amendments to IAS 41: Agriculture

As part of its 2018-2020 annual improvements to the IFRS process, the IASB issued amendments to IAS 41. The amendment removes the requirement in paragraph 22 of IAS 41 for entities to exclude taxation cash flow when measuring the fair value of a biological asset using a present value technique. This will ensure consistency with the requirements in IFRS 13 "Fair Value Measurement". The amendment is effective for annual reporting periods beginning on or after January 1, 2023. The Company notes the amendment is not relevant for the Company's fair value measurement methodology.

# (v) Definition of Accounting Estimates (Amendments to IAS 8)

On February 12, 2021, the IASB issued Definition of Accounting Estimates (Amendments to IAS 8). The amendments introduce a new definition for accounting estimates, clarifying that they are monetary amounts in the financial statements that are subject to measurement uncertainty. The amendments also clarify the relationship between accounting policies and accounting estimates by specifying that a company develops an accounting estimate to achieve the objective set out by an accounting policy. The amendments are effective for annual periods beginning on or after January 1, 2023 with early adoption permitted. The Company is currently evaluating the potential impact of these amendments on the Company's consolidated financial statements.

#### (vi) Disclosure Initiative – Accounting Policies (Amendments to IAS 1 and IFRS Practice Statement 2)

On February 12, 2021, the IASB issued Disclosure Initiative – Accounting Policies (Amendments to IAS 1 and IFRS Practice Statement 2 Making Materiality Judgements). The amendments help companies provide useful accounting policy disclosures.

The key amendments include:

- Requiring companies to disclose their material accounting policies rather than their significant accounting policies;
- Clarifying that accounting policies related to immaterial transactions, other events or conditions are themselves immaterial and as such need not be disclosed; and
- Clarifying that not all accounting policies that relate to material transactions, other events or conditions are themselves
  material to a company's financial statements.

The amendments are effective for annual periods beginning on or after January 1, 2023 with early adoption permitted. The Company is currently evaluating the potential impact of these amendments on the Company's consolidated financial statements.

#### Notes to the Condensed Interim Consolidated Financial Statements

For the three-month periods ended February 28, 2023 and February 28, 2022

(Unaudited, Expressed in Thousands of Canadian Dollars Except Share Amounts)

#### 4 Accounts receivable

As of February 28, 2023 and November 30, 2022, accounts receivable consisted of:

	February 28, 2023	November 30, 2022
Trade accounts receivable	\$ 6,996	\$ 4,409
	\$ 6,996	\$ 4,409

As of February 28, 2023, the Company performed an analysis over its aged receivables balance by customer. The Company notes that credit risk is generally limited to receivables from government bodies, which generally have low default risk. From the review, the Company noted that no further AFDA is required and the Company recognized a \$nil provision for expected credit losses at February 28, 2023 (November 30, 2022 - \$nil).

# 5 Prepaid expenses

As of February 28, 2023 and November 30, 2022, prepaid expenses consisted of:

	Feb	ruary 28, 2023	November 30, 2022
Insurance	\$	548 \$	361
Packaging material prepayments		429	709
Deposits and other		1,066	621
	\$	2,043 \$	1,691

# 6 Biological assets

The Company measures biological assets consisting of cannabis plants at fair value less costs to sell up to the point of harvest, which becomes the basis for the cost of finished goods inventories after harvest.

The changes in the carrying value of biological assets for the three months ended February 28, 2023 and the year ended November 30, 2022 are as follows:

	February 28, 2023	November 30, 2022
Carrying amount, opening	\$ 4,146	\$ 1,948
Flowr Okanagan acquisition	278	
Production costs Changes in fair value less costs to sell due to biological	3,304	9,342
transformation	2,554	1,946
Transferred to inventory upon harvest	(6,089)	(9,090)
	\$ 4,193	\$ 4,146

The significant estimates and assumptions used to determine the fair value of the cannabis plants include:

- Estimated stage of growth of the cannabis up to the point of harvest;
- Expected yield by strain of plant; and
- Fair value less selling costs.

The Company's estimates are, by their nature, subject to change and differences from anticipated yield which will be reflected in the gain or loss on biological assets in future periods.

On average, the growth cycle is between 14 to 17 weeks and the Company expects average yield per plant to be between 71 to 99 grams of harvested flower and 10 to 32 grams of harvested trim. As at February 28, 2023, it is estimated that the Company's biological assets will yield approximately 998,472 grams of flower and 313,650 grams of trim when harvested.

The Company has determined the average fair value less cost to sell to be \$3.92 per gram of flower and \$0.20 per gram of trim. As of February 28, 2023, a change of 10% in the estimated yield per plant, growth cycle and fair value less cost to sell of dry cannabis would result in the variances noted below to the fair value of biological assets.

#### Notes to the Condensed Interim Consolidated Financial Statements

For the three-month periods ended February 28, 2023 and February 28, 2022

(Unaudited, Expressed in Thousands of Canadian Dollars Except Share Amounts)

These inputs are level 3 on the fair value hierarchy and are subject to volatility in market prices and several uncontrollable factors, which could significantly affect the fair value of biological assets in future periods.

Assumption	February 28, 2023	+/- 10%
Yield per plant	71 – 99 grams of flower and 10 – 32 grams of trim per plant	\$392
FV less cost to sell	\$3.92 per gram of flower and \$0.20 per gram of trim	\$1,515
Estimated stage of growth	0% - 100% of Life Cycle per stage	\$392

# 7 Inventory

The Company's inventories are comprised of the following balances as at February 28, 2023 and November 30, 2022:

	Fe	bruary 28, 2023	November 30, 2022
Dry cannabis	\$	\$	
Available for packaging		10,637	7,947
Packaged inventory		1,175	1,277
Trim		404	317
Concentrates		245	290
Packaging Materials		734	630
	\$	13,195 \$	10,461

As at February 28, 2023, the Company had dry cannabis with a carrying value of \$11,812 (November 30, 2022: \$9,224) and harvested trim with a carrying value of \$404 (November 30, 2022: \$317).

The Company holds 4,468,915 grams of harvested cannabis (November 30, 2022: 3,301,033 grams), which is comprised of 2,532,435 grams of harvested flower and 1,936,479 grams of harvested trim (November 30, 2022: 2,053,394 grams of harvested flower and 1,247,639 grams of harvested trim).

During the period ended February 28, 2023, the Company recorded \$4,427 of production costs (February 28, 2022: \$2,092). Included in the production costs for the period ended February 28, 2023 was \$918 of amortization of property and equipment and right-of-use assets (February 28, 2022 \$325).

# 8 Intangible assets and goodwill

	Intangible asset	Goodwill
Balance - November 30, 2021	3,202	182
Addition from 3PL acquisition	2,337	5,842
Depreciation	(1,670)	-
Balance - November 30, 2022	3,869	6,024
Depreciation	(466)	-
Balance – February 28, 2023	3,404	6,024

The Company's intangible assets and goodwill were acquired through the acquisition of ACC & 3PL during the years ended November 30, 2018 and 2022, respectively. The Company's intangible assets, licenses to sell cannabis, were considered definite lived. The useful lives of the licenses are 2.16 years and 6.08 years. The Company completes an annual assessment of the recoverable amount of the goodwill. The recoverable amount of the ACC CGU and 3PL CGU, to which goodwill are allocated, were determined based on the fair value less costs of disposal using Level 3 inputs in a discounted cash flow analysis.

# **Notes to the Condensed Interim Consolidated Financial Statements**

For the three-month periods ended February 28, 2023 and February 28, 2022

(Unaudited, Expressed in Thousands of Canadian Dollars Except Share Amounts)

# 9 Property, plant and equipment

	Land	Buildings	Construction in-process	Growing and processing equipment	Right-of-use asset	Leasehold Improvements		
			-	equipment		-	Other	Total
Cost								
Balance - November 30, 2021	\$ 1,348	\$ 9,235	\$ 3,201	5,207	1,117	1,067	276	21,451
Additions – 3PL acquisition	-	-	-	3,340	2,872	6,700	11	12,923
Additions	-	5	1,169	84	-	165	21	1,444
Disposals	-	-	-	(91)	-	-	-	(91)
Balance - November 30, 2022	1,348	9,240	4,370	8,540	3,989	7,932	308	35,727
Additions – Flowr acquisition	-	-	-	2,755	3,031	5,330	-	11,116
Additions	-	18	605	248	460	30	17	1,378
Disposals	-	-	-	-	-	-	-	-
Balance – February 28, 2023	1,348	9,259	4,975	11,543	7,480	13,292	325	48,221
Accumulated amortization								
Balance - November 30, 2021	-	(1,440)	-	(1,408)	(611)	(705)	(218)	(4,382)
Additions	-	(486)	-	(724)	(512)	(938)	(34)	(2,694)
Disposals	-	-	-	0	-	-	-	-
Balance - November 30, 2022	-	(1,926)	-	(2,132)	(1,123)	(1,643)	(252)	(7,076)
Additions	-	(122)	-	(237)	(203)	(413)	(10)	(985)
Disposals	-	-	-	0	-	-	-	-
Balance - February 28, 2023	-	(2,048)	-	(2,369)	(1,326)	(2,056)	(262)	(8,061)
Net book value								
November 30, 2022	\$ 1,348	\$ 7,314	\$ 4,370	\$ 6,408	\$ 2,866	\$ 6,289	\$ 56	\$ 28,651
February 28, 2023	1,348	7,210	4,975	9,174	6,154	11,236	63	40,160

#### Notes to the Condensed Interim Consolidated Financial Statements

For the three-month periods ended February 28, 2023 and February 28, 2022

(Unaudited, Expressed in Thousands of Canadian Dollars Except Share Amounts)

# 10 Investment in associate and joint venture

#### Investment in associate

	February 28, 2023	November 30, 2022
Opening balance	\$ -	\$ 3,951
Cash advanced under shareholder loan	-	802
Equity gain on investment	-	1,233
Fair value gain on acquisition of investment (Note 12)	-	1,115
Effective settlement of shareholder loan	-	(3,701)
Acquisition of investment (Note 12)	-	(3,400)
	\$ -	\$ <u>-</u>

During the year ended November 30, 2018, the Company acquired 49% of the issued and outstanding common shares of 3PL. The Company paid \$49 cash and issued 1,225,490 common shares of the Company pursuant to a series of agreements related to the acquisition of the Company's interest in 3PL (together, the "Purchase Agreement") with its one other shareholder. The other shareholder of 3PL committed to provide a maximum of up to \$9,000 in funding for 3PL through shareholder loans to finance the construction and equipping of the facility.

Pursuant to the Purchase Agreement, on April 23, 2019, the Company issued an additional 1,953,125 common shares to the other shareholder. The fair value of the common shares issued was determined to be \$1,250. In addition, the Company also has the option to purchase the remaining 51% interest from the other shareholder upon receipt of 3PL's sales license from Health Canada. On August 20, 2021, 3PL was issued standard cultivation, standard processing and medical sales licenses, in accordance with Health Canada's *Cannabis Act* and regulations ("CA&R"). On May 10, 2022, 3PL received a sales amendment license from Health Canada.

On June 1, 2022, the Company entered into an amended shareholders agreement to increase the Company's ownership stake from 49% to 50%. In addition to increasing the Company's ownership stake, the amended agreement also increased the Company's substantive rights over the 3PL entity while removing certain substantive rights from the current non-controlling interest shareholder. As such, under IFRS 3 "Business Combinations" guidance the Company acquired control over 3PL effective on June 1, 2022. As a result, 3PL was no longer accounted for as an investment in associate from June 1, 2022. A fair value gain on acquisition was recorded for \$1,115 as part of the step-acquisition for the original 49% ownership interest and acquired 1% ownership interest. Please refer to Note 12 for further information.

# Investment in joint venture

	February 28, 2023	November 30, 2022
Opening balance	\$ 1,000	\$ -
Initial investment in joint venture	-	1,000
Cash advanced	1,845	-
Acquisition of control of joint venture (Note 11)	(2,845)	-
	\$ -	\$ 1,000

During the year ended November 30, 2022, the Company invested \$1,000 into a joint-venture and subscribed for 50% of the common shares of the Avant K1 joint-venture. During the period ended February 28, 2023 the Company increased the Company's substantive rights over the Avant K1 joint-venture and operations of the joint ventures acquisition (note 11). As such, under IFRS 3 guidance the Company acquired control over the Avant K1 joint venture effective on February 2, 2023.

#### Notes to the Condensed Interim Consolidated Financial Statements

For the three-month periods ended February 28, 2023 and February 28, 2022

(Unaudited, Expressed in Thousands of Canadian Dollars Except Share Amounts)

# 11 Acquisitions

# Acquisition of 3PL (Provisional)

On June 1, 2022, the Company entered into an amended agreement to increase the Company's ownership stake in 3PL from 49% to 50%. In addition to increasing the Company's ownership stake, the amended agreement also increased the Company's substantive rights over the 3PL entity while removing certain substantive rights from the current non-controlling interest shareholder. As such, under IFRS 3 guidance the Company acquired control over 3PL effective on June 1, 2022.

The execution of the amended agreement constituted a step acquisition business combination under IFRS 3, Business Combinations. The acquisition date fair value of the equity interest held by the Company immediately before the acquisition date was \$3,400, resulting in \$1,115 gain on remeasuring the equity interest on acquisition.

As of June 1, 2022, the Company recognized \$3,400 in non-controlling interest representing the 50% ownership stake, which was valued using the acquisition date fair value. The non-controlling interest has protective rights over the 3PL entity, but none which would significantly restrict the Company's ability to exert control over 3PL.

The Company has settled \$3,076 in pre-existing relationships it had with 3PL as of June 1, 2022. This balance includes settled amounts for accounts receivable, accounts payable and accrued liabilities, and a shareholder loan payable.

Management is in the process of gathering the relevant information that existed at the acquisition date to determine the net identifiable assets acquired and liabilities assumed. As such, the initial purchase price was provisionally determined and allocated based on the Company's estimated fair value of the identifiable assets acquired and the liabilities assumed on the acquisition date. The values assigned are, therefore, preliminary and subject to change. Management continues to refine and finalize the acquisition-date initial fair value of goodwill and deferred taxes.

Consideration (provisional)	Amount	
Acquisition-date fair value of initial 49% interest (Note 10)	\$	3,332
Fair value Consideration for 1% interest acquired		68
Non-controlling interest - fair value		3,400
Pre-existing relationships		3,076
Total fair value of consideration		9,876

Net assets acquired (provisional)	-	Amount
Current assets		
Cash	\$	59
Accounts receivable		19
Prepaid expenses		221
Inventory		2,489
Biological assets		1,869
Non-current assets		
Intangible assets		2,337
Property, plant and equipment		12,923
Total assets		19,917
Current liabilities		
Accounts payable and accrued liabilities	\$	356
Lease liability		313
Non-current liabilities		
Lease liability		2,559
Deferred tax liability		741
Amount due to non-controlling interests		11,914
Total liabilities		15,883
Total net assets acquired		4,034

#### Notes to the Condensed Interim Consolidated Financial Statements

For the three-month periods ended February 28, 2023 and February 28, 2022

(Unaudited, Expressed in Thousands of Canadian Dollars Except Share Amounts)

Purchase price allocation (provisional)	Amount
Net identifiable assets acquired	\$ 4,034
Goodwill	5,842
Total fair value of consideration	9,876

Net cash flows	Amount
Cash consideration paid	\$ -
Cash acquired	59
Total net cash flows	59

Goodwill arising from the business combination represents expected synergies, future income and growth that are not separately recognized.

### **Acquisition of Flowr Okanagan (Provisional)**

On February 2, 2023, the Company, through its controlled subsidiary Avant K1, entered into an agreement to acquire 100% of the outstanding shares of Flowr Okanagan. As such, under IFRS 3 guidance the Company acquired control over Flowr Okanagan effective on February 2, 2023.

The consideration paid at closing was \$5,330, which is comprised of \$1,653 cash, 7,402,186 common shares valued at \$1,480, and a financing liability settled of \$2,197.

Management is in the process of gathering the relevant information that existed at the acquisition date to determine the fair value of the net identifiable assets acquired and liabilities assumed of Flowr Okanagan. As such, the initial purchase price was provisionally determined and allocated based on the Company's estimated fair value of the initial interest, identifiable assets acquired and the liabilities assumed on the acquisition date. The values assigned are, therefore, preliminary and subject to change. Management continues to refine and finalize the purchase price allocation for the fair value of property, plant and equipment, lease liability and right of use asset, intangible assets, goodwill and deferred taxes.

Consideration (provisional)	Amount
Cash	\$ 1,653
Share consideration	1,480
Financing liability settled	2,197
Non controlling interests – proportionate share of net identifiable assets	5,330
Total fair value of consideration	10,660

Net assets acquired (provisional)	Amount
Current assets	
Cash	\$ 3
Accounts receivable	1,222
Prepaid expenses	857
Inventory	832
Biological assets	278
Non-current assets	
Property, plant and equipment	11,117
Total assets	14,309
Current liabilities	
Accounts payable and accrued liabilities	\$ 618
Lease liability	-
Non-current liabilities	

#### Notes to the Condensed Interim Consolidated Financial Statements

For the three-month periods ended February 28, 2023 and February 28, 2022

(Unaudited, Expressed in Thousands of Canadian Dollars Except Share Amounts)

Lease liability		3,031
Deferred tax liability		-
Total liabilities		3,649
Total net assets acquired		10,660
Purchase price allocation (provisional)		Amount
Net identifiable assets acquired	\$	10,660
Total fair value of consideration		10,660
Net cash flows		Amount
Cash consideration paid	\$	(1,653)
Cash acquired	·	3
Total net cash flows		1,650

Goodwill arising from the business combination represents expected synergies, future income and growth that are not separately recognized.

During the period ended February 28, 2023, the Company's consolidated revenue included \$371 from Flowr Okanagan. In addition, for the period ended February 28, 2023, the Company's consolidated loss and comprehensive loss included net loss of \$120 respectively from Flowr Okanagan. If Flowr Okanagan was acquired December 1, 2022, the Company's consolidated revenue would include \$371 from Flowr Okanagan and comprehensive loss would include net loss of \$120 respectively from Flowr Okanagan.

# 12 Partly-owned subsidiaries

Proportion of equity interest held by non-controlling interests:

	Subsidiaries	Geographical Region	Ownership percentage February 28, 2023	Ownership percentage November 30, 2022	
3PL		Vernon, British Columbia	-%		50%

On June 1, 2022, the Company entered into an amended agreement to increase the Company's ownership stake in 3PL from 49% to 50%. In addition to increasing the Company's ownership stake, the amended agreement also increased the Company's substantive rights over the 3PL entity while removing certain substantive rights from the current non-controlling interest shareholder. As such, under IFRS 3 guidance the Company acquired control over 3PL effective on June 1, 2022.

On February 1, 2023, the Company entered into a purchase agreement to acquire the remaining 50% non-controlling interests of 3PL, increasing its ownership interest to 100%. The consideration paid at closing is outlined in the schedule below.

Consideration	Amount
Cash	\$ 1,500
Convertible promissory note – liability component	8,980
Convertible promissory note – equity component	515
Share consideration	3,905
Share purchase warrants (note 15)	341
Less: Financing liability settled	(11,989)
Implied FV of 50% of equity	3,252
Less: Carrying value of non-controlling interest	(4,252)
Difference recognized in deficit	1,000

#### Notes to the Condensed Interim Consolidated Financial Statements

For the three-month periods ended February 28, 2023 and February 28, 2022

(Unaudited, Expressed in Thousands of Canadian Dollars Except Share Amounts)

Subsidiaries	Geographical Region	Ownership percentage February 28, 2023	Ownership percentage November 30, 2022	
Avant K1	Kelowna, British Columbia	50%		50%

During the period ended February 28, 2023 the Company increased the Company's substantive rights over the Avant K1 joint-venture and operations of the joint ventures acquisition (note 11). Specifically, running the day-to-day operations of the Avant K1 entity and the TFGOK subsidiary. As such, under IFRS 3 guidance the Company acquired control over the Avant K1 joint venture effective on February 2, 2023.

# 13 Lease liability

The following is the continuity of lease liability, for the period ended February 28, 2023:

Balance - November 30, 2021	623
Addition from 3PL acquisition	2,872
Lease payments	(696)
Interest expense on lease liability	212
Balance - November 30, 2022	3,011
Addition from Flowr Okanagan acquisition	3,031
Lease modification	428
Lease payments	(244)
Interest expense on lease liability	89
Balance – February 28, 2023	6,315
Current portion	717
Long-term portion	5,598

The Company recognized right-of-use assets and a corresponding lease liability upon the adoption of IFRS 16 related to its facility premises and corporate office. The lease modification relates to the extension of the corporate office lease for a two-year period. Amortization on the right-of-use asset is calculated over the term of the lease. Interest expense of \$12 (February 28, 2022: \$37) is included in financing costs and payments are applied against the lease liability.

#### 14 Convertible debentures

Accounting Policy, Estimates & Judgements.

Convertible debentures are financial instruments which are accounted for separately dependent on the nature of their components: a financial liability and an equity instrument. The identification of such components embedded within a convertible debenture requires significant judgment given that it is based on the interpretation of the substance of the contractual arrangement. Where the conversion option has a fixed conversion rate, the financial liability, which represents the obligation to pay coupon interest on the convertible debentures in the future, is initially measured at its fair value and subsequently measured at amortized cost. The residual amount is accounted for as an equity instrument at issuance. Where the conversion option has a variable conversion rate, the conversion option is recognized as a derivative liability measured at fair value through profit and loss. The residual amount is recognized as a financial liability and subsequently measured at amortized cost. The determination of the fair value is also an area of significant judgment given that it is subject to various inputs, assumptions and estimates including: contractual future cash flows, discount rates, credit spreads and volatility.

Transaction costs are apportioned to the debt liability and equity components in proportion to the allocation of proceeds.

#### Notes to the Condensed Interim Consolidated Financial Statements

For the three-month periods ended February 28, 2023 and February 28, 2022

(Unaudited, Expressed in Thousands of Canadian Dollars Except Share Amounts)

# Explanatory information

The following is the continuity of convertible debentures, for the period ended February 28, 2023:

	February 28, 2023
Principal amount (note 12)	9,500
Liability component amount, beginning of period	8,980
Principal and interest payments	<u>-</u>
Conversion costs and other	<u>-</u>
Liability component carrying value, end of period	8,980
Equity component amount, beginning of period	515
Principal and interest payments	<u>-</u>
Conversion costs and other	<u>-</u>
Equity component carrying value, end of period	515
Liability component current portion	6,334
Liability component long-term portion	2,646

On February 1, 2023, the Company issued convertible debentures to the non-controlling interests of 3PL for gross proceeds of \$9,500 under the following terms: (i) a maturity date of August 1, 2024; (ii) an interest rate of 10% per annum, payable quarterly; and (iii) convertible at \$0.50 per share.

# 15 Share capital

The Company has an unlimited number of common shares without par value authorized for issuance. The Company also has an unlimited number of preference shares without par value authorized for issuance.

#### (a) Issued shares

During the period ended February 28, 2023:

- The Company issued 931,406 common shares to service providers in connection with services received, resulting in a decrease to contributed surplus of \$24 and an increase in share capital of \$188.
- The Company issued 902,665 common shares in connection with employment compensation agreements, resulting
  in a decrease to contributed surplus of \$355 and an increase in share capital of \$279.
- The Company issued 22,249,734 common shares valued at \$3,906 in connection with the purchase of the non-controlling interests of 3PL. \$145 in transaction costs from the purchase were charged to equity.
- The Company issued 7,402,186 common shares valued at \$1,480 in connection with the acquisition of Flowr Okanagan.

During the period ended February 28, 2022:

• The Company issued 1,000,000 common shares with a fair value of \$280 pursuant to an amending agreement with the vendors of Grey Bruce in connection with achieving certain milestones (note 18).

#### (b) Escrow shares

As at February 28, 2023 there were 1,489,225 common shares held in escrow. The following is a summary of escrow shares to be released:

Escrow release date	Escrow shares to be released	Escrow Balance
April 30, 2023	403,512	1,085,713

Of the common shares held in escrow summarized in the table above, as at February 28, 2023 there were:

#### Notes to the Condensed Interim Consolidated Financial Statements

For the three-month periods ended February 28, 2023 and February 28, 2022

(Unaudited, Expressed in Thousands of Canadian Dollars Except Share Amounts)

- 1,085,713 common shares held in escrow pursuant to an agreement with a consulting firm to facilitate the acquisition and cultivation of cannabis genetics, which will be released contingent upon the occurrence of future events.
- 403,512 common shares held in escrow pursuant to the debt financing, with April 30, 2023 being the final scheduled release.

#### (c) Share purchase warrants

Warrant transactions are summarized as follows:

	Number of share purchase warrants	Weighted average exercise price
Balance - November 30, 2021 and November 30, 2022	36,816,250	0.90
Granted	5,000,000	0.50
Balance – February 28, 2023	41,816,250	\$ 0.85

On February 1, 2023, the Company granted 5,000,000 share purchase warrants in connection with the purchase of 3PL's non controlling interests. Fair value inputs to the warrants were an exercise price of \$0.50, measurement date share price of \$0.20, volatility of 110.1%, risk free rate of 3.66%, barrier of 1.25 and an expiry date of February 1, 2025. The fair value of the warrants was calculated using the barrier option pricing model.

The weighted average outstanding life of warrants outstanding as at February 28, 2023 is 1.18 years.

At February 28, 2023 the following share purchase warrants were outstanding:

Number of share purchase warrants	Exercise price p	er share	Expiry date
6,772,500	\$	0.30	March 8, 2024
1,293,750	\$	0.80	March 30, 2024
28,750,000	\$	1.04	March 30, 2024
5,000,000	\$	0.50	February 1, 2025
41,816,250			

# (d) Restricted Stock Units and Deferred Stock Units ("RSUs" and "DSUs")

RSUs and DSUs are granted to the Company's directors, officers, and employees as a part of compensation under the terms of the Company's deferred and restricted share unit plans. Each RSU and DSU entitles the participant to receive the value of one Common Share of the Company. The maximum number of awards of RSUs, DSUs and all other security-based compensation arrangements shall not exceed 10% of the Company's outstanding shares.

The number of RSUs and DSUs awarded and underlying vesting conditions are determined by the Board of Directors in its discretion. RSUs and DSUs are accounted for as equity settled share-based payments and are valued using the share price of the Common Share on grant date. Since the Company controls the settlement, the RSUs and DSUs are considered equity settled.

RSU and DSU transactions are summarized as follows:

	Number of RSUs and DSUs	Weighted average issue price		
Balance – November 30, 2021	-	\$ -		
Granted	9,184,814	0.27		
Vested and released	(4,093,766)	0.27		
Forfeited	(74,076)	0.27		
Balance - November 30, 2022	5,016,972	\$ 0.27		
Granted	1,143,716	0.22		
Vested and released	(2,241,749)	0.25		
Forfeited	(7,409)	0.27		
Balance – February 28, 2023	3,911,530	\$ 0.27		

#### Notes to the Condensed Interim Consolidated Financial Statements

For the three-month periods ended February 28, 2023 and February 28, 2022

(Unaudited, Expressed in Thousands of Canadian Dollars Except Share Amounts)

The weighted average outstanding life of RSUs and DSUs outstanding as at February 28, 2023 is 0.001 years. Share based payments included \$172 of RSU and DSU expense. RSUs and DSUs generally vest in tranches across a twelve-month period.

At February 28, 2023 the following RSUs and DSUs warrants were outstanding:

Grant date	Number of RSUs and DSUs
March 1, 2022	3,608,703
December 28, 2022	132,372
February 22, 2023	170,455
	3,911,530

# 16 Stock-based compensation

The Company provides stock-based compensation to its directors, officers, employees, and consultants through grants of stock options.

# (a) Stock options

The Company has adopted a stock option plan (the "Plan") to grant options to directors, officers, employees and consultants. Under the Plan, the Company may grant options that shall not exceed 10% of the total number of issued common shares of the Company (calculated on a non-diluted basis) at the time an option is granted. Options granted can have a term of up to ten years and an exercise price typically not less than the Company's closing stock price on the TSX on the last trading day before the date of grant. Vesting is determined at the discretion of the Board of Directors.

Stock option transactions are summarized as follows:

	Number of shares	Weighted average exercise price		
Balance – November 30, 2021	3,537,500	\$	0.41	
Granted	5,095,000		0.27	
Expired/cancelled	(1,285,000)		0.50	
Balance - November 30, 2022	7,347,500	\$	0.30	
Granted	-		-	
Expired/cancelled	(250,000)		0.64	
Balance – February 28, 2023	7,097,500 \$		0.29	

The weighted average outstanding life of stock options outstanding as at February 28, 2023 is 1.85 years.

At February 28, 2023, the following stock options were outstanding:

Number of shares	<b>Options Vested</b>	Exercise price per share	Expiry date
1,500,000	1,500,000	\$0.34	August 14, 2024
100,000	100,000	\$0.30	September 25, 2024
387,500	387,500	\$0.30	October 23, 2024
50,000	50,000	\$0.30	August 12, 2023
5,060,000	4,920,000	\$0.27	February 28, 2025
7,097,500	7,027,500	\$0.29	

#### (b) Share based payments

During the period ended February 28, 2023, the Company recognized share-based payment expense of \$321 (February 28, 2022: \$22) that was recorded in the condensed interim consolidated statements of comprehensive loss. The share-based payments represent the fair value of stock options granted or vested during the period ended February 28, 2023 and are

#### Notes to the Condensed Interim Consolidated Financial Statements

For the three-month periods ended February 28, 2023 and February 28, 2022

(Unaudited, Expressed in Thousands of Canadian Dollars Except Share Amounts)

estimated on the grant date using the Black-Scholes option pricing model. The share-based payments also consist of common shares issued for services during the year. In addition, stock options granted to consultants for services to be provided over a period of time are recorded as prepaid expenses until the service period has lapsed.

#### 17 Net Revenue

	Febru	February 28, 2023		uary 28, 2022
Recreational revenue	\$	4,147	\$	2,531
Bulk cannabis sales		2,806		1,507
Medical revenue		52		57
Management fees and other revenue		24		102
	\$	7,029	\$	4,197

# 18 Related party transactions

# Key management compensation

All transactions with related parties have occurred in the normal course of operations. Key management is comprised of directors and executive officers.

Key management compensation for the periods ended February 28, 2023 and February 28, 2022 consists of the following:

	Feb	oruary 28, 2023	Feb	oruary 28, 2022
Salaries and wages	\$	183	\$	197
Director fees		68		37
Share-based payments		1		22
	\$	252	\$	256

#### Related party balances

As at February 28, 2023, accounts payable included \$nil (November 30, 2022: \$nil) which was due to directors of the Company in connection with directors' fees.

#### Related party transactions

During the year ended November 30, 2017, GreenTec Holdings Ltd. entered into share purchase agreements to purchase 100% interest in Grey Bruce, 1118157 B.C. Ltd., Zenalytic Laboratories Ltd. and GBP. Each one of these entities was under common control with two of the Company's executive officers. Certain milestones within these agreements remain outstanding and are disclosed under Note 22.

#### 19 Financial instruments

#### a) Financial instruments

The Company's financial instruments consist of cash and cash equivalents, accounts receivable, marketable securities, deposits, investment in associate, accounts payable and lease liabilities. The Company is exposed to certain financial risks, including credit risk, liquidity risk and market risk.

#### i) Credit risk

Credit risk is the risk of an unexpected loss if a customer or third party to a financial instrument fails to meet its contractual obligations and arises principally from the Company's cash and accounts receivable. At present, the Company holds its cash in Canadian Charted Banks and will only consider investment of excess cash in highly rated government and corporate debt securities or guaranteed certificates from Canadian chartered banks. The Company has established guidelines, including diversification, credit ratings and maturities, to ensure safety and liquidity of its cash. Over 51% of the Company's trade accounts receivable balance at February 28, 2023 is due from a governmental agency. Subsequent to quarter-end, the Company has collected on 67% of the receivable balance. The Company does not have a history of inability to collect on its trade accounts receivable and all balances due at February 28, 2023, are considered collectible.

#### Notes to the Condensed Interim Consolidated Financial Statements

For the three-month periods ended February 28, 2023 and February 28, 2022

(Unaudited, Expressed in Thousands of Canadian Dollars Except Share Amounts)

As at February 28, 2023, the Company's exposure is the carrying value of the financial instruments. The Company's maximum exposure to credit risk is the carrying value of its financial assets.

#### ii) Currency risk

The Company operates primarily in Canadian dollars and as such is not affected by the fluctuations of the Canadian dollar with other currencies.

#### iii) Liquidity risk

Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they come due. To the extent that the Company does not believe it has sufficient liquidity to meet its current obligations, the Board considers securing additional funds through issuances of equity and debt or partnering transactions. The Board approves any material transactions outside the ordinary course of business. Management regularly reviews the Company's operating and capital budgets and maintains short-term cash flow forecasts.

The Company monitors its risk of shortage of funds by monitoring the maturity dates of existing trade and other accounts payable.

# iv) Maturity risk

The Company's cash and cash equivalents balance at February 28, 2023 was \$2,588. At February 28, 2023, the Company had accounts receivable of \$6,996, accounts payable and accrued liabilities of \$4,543, current lease liabilities of \$717, long-term lease liabilities of \$5,598, amount due to non controlling interest of \$1,005, current debenture payable of \$6,334 and a non-current debenture payable of \$2,646. All accounts payable and accrued liabilities are current.

As at February 28, 2023, the Company did not have derivative financial liabilities with contractual maturities.

Typically, the Company ensures that it has sufficient cash on demand to meet expected operational expenses and commitments for a period of 90 days. To achieve this objective, the Company prepares annual operating and capital expenditure budgets, which are regularly monitored and updated as considered necessary.

The following table summarizes the maturities of the Company's financial liabilities as at November 30, 2022 based on the undiscounted contractual cash flows:

	Carr	ying value	Princ	ipal amount	Less	than 1 year	1 - 5 years
Accounts payable	\$	4,543	\$	4,543	\$	4,543	\$ -
Lease liabilities		6,315		12,513		1,291	11,222
Amount due to non controlling interest		1,005		1,005		-	1,005
Convertible debenture		8,980		9,500		6,334	3,166
	\$	20,843	\$	27,561	\$	12,168	\$ 15,393

#### b) Interest rate risk

Current financial assets and financial liabilities are generally not exposed to interest rate risk because of their short-term nature and maturity.

Sensitivity analysis has not been presented as the Company currently has no significant exposure in its operations to interest rate or currency exchange rate fluctuations as the Company's interest-bearing liabilities have fixed interest rate.

#### c) Fair value classification of financial instruments

		Fair Value through	
	Amortized cost \$	Profit or Loss \$	Total \$
Assets			
Cash	2,588	-	2,588
Accounts receivable	6,996	-	6,996
Marketable securities	-	19	19
iabilities			
Accounts payable and accrued liabilities	4,543	-	4,543
Amount due to non controlling interest	1,005	-	1,005

#### Notes to the Condensed Interim Consolidated Financial Statements

For the three-month periods ended February 28, 2023 and February 28, 2022

(Unaudited, Expressed in Thousands of Canadian Dollars Except Share Amounts)

Lease liabilities6,315-6,315Convertible debenture payable8,980-8,980

Fair value measurement is based on a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value which are:

Level 1 — measurement based on quoted prices (unadjusted) observed in active markets for identical assets and liabilities.

Level 2 — measurement based on inputs other than quoted prices included in Level 1, that are observable for the asset and liability.

Level 3 — measurement based on inputs that are not observable (supported by little or no market activity) for the asset or liability.

At February 28, 2023, the Company had Level 1 financial instruments, consisting of cash and cash equivalents and marketable securities, with a fair value of \$2,607 (November 30, 2022; \$6,780). The Company has no level 3 financial instruments.

At February 28, 2023, the Company had Level 2 financial instruments, consisting of the convertible debenture payable (equity and liability components), with a fair value of \$515 and \$8,980 (November 30, 2022: \$nil). The fair value of the equity component was measured at fair value based on a barrier option pricing model. The primary inputs that drove the value were the strike price, volatility, discount rate (risk-free rate), and barrier.

# 20 Capital management

The Company's capital structure consists of shareholders' equity. The Company's objective when managing capital is to maintain adequate levels of funding to support the development of its businesses and maintain the necessary corporate and administrative functions to facilitate these activities. Future financings are dependent on market conditions and there can be no assurance the Company will be able to raise funds in the future. The Company is not subject to externally imposed capital requirements. The Company may raise additional debt or equity financing in the near future to meet its obligations.

#### 21 Commitments and contingencies

From time to time, the Company is engaged in various legal proceedings and claims that have arisen in the normal course of business. The outcome of all the proceedings and claims against the Company is subject to future resolution, including the uncertainties of litigation. Management believes that the probable ultimate resolution of any such proceedings and claims, individually or in the aggregate, will not have a material adverse effect on the financial condition of the Company. As of February 28, 2023, the Company has accrued a provision of \$100 related to certain legal proceedings for which the outcome is uncertain at this time.

Additionally, the Company may enter into contracts for services in the normal course of operations. The Company's current contractual commitments vary in terms and can be terminated upon sufficient notice. The Company has the following outstanding commitments based on achieving certain milestones.

#### **Grey Bruce**

On March 13, 2020, the Company entered into an amending agreement with the vendors of Grey Bruce amending certain terms and conditions of the definitive share purchase agreement, dated September 15, 2017. During the period ended November 30, 2022, the final milestone related to Grey Bruce was settled and the Company issued 1,000,000 common shares in connection with the milestone.

# **GBP**

As at November 30, 2022, in connection with a previously completed asset acquisition, the Company has committed to issue common shares valued at \$2,500 contingent on future events as follows:

Trigger event	
Completion of GBP construction of a Health Canada approved cannabis production	
facility in compliance with the CA&R	\$ 500
GBP obtaining a license to sell cannabis under the CA&R	500
GBP having sold an aggregate of 3,000 kg of dried cannabis	750

#### Notes to the Condensed Interim Consolidated Financial Statements

For the three-month periods ended February 28, 2023 and February 28, 2022

(Unaudited, Expressed in Thousands of Canadian Dollars Except Share Amounts)

GBP completing construction of an expansion to its production facility to increase production by at least 8,500 kg per annum and receiving an amendment to its production and sales licences

750

\$ 2,500

On March 13, 2020, the Company entered into an amending agreement with the vendors of GBP amending certain terms and conditions of the definitive share purchase agreement dated November 15, 2017.

The vendors of GBP agreed to reduce their entitlement to a portion of the purchase price such that the remaining payment obligations of the Company in connection with the acquisition of GBP were reduced by \$5,750. In addition to reducing the milestone payments, the vendors of GBP agreed to restructure the remaining milestones, as shown in the above table and raise the floor price of the common shares to be issued in connection with the new milestones to a deemed price per share equal to the greater of (A) the 10-day volume-weighted average trading price of the Company's common shares, and (B) \$1.00. Of the \$5,750 reduction to the Company's payment obligations, \$5,615 of the remaining milestone payments was waived by an executive officer of the Company.

# 22 Subsequent Events

On March 14, 2023, The Company closed its acquisition of the remaining 50% equity stake in Avant K1 from the other 50% partner. The aggregate purchase price payable pursuant to the terms of the Agreement was equal to approximately \$4.56 million which was satisfied with the issuance of a promissory note in the principal amount of approximately \$1.45 million, which shall bear interest at a rate of 12% per annum and mature and become due and payable on September 14, 2023; and the issuance of 18,137,780 common shares in the capital of Avant.